TLR7 and neoplasm: The Lin group reported that surface modification of Hf-DBP reactivates innate immunity by co-delivering a Toll-like receptor 7 (TLR-7) agonist, imiquimod, and an anti-CD47 antibody (αCD47) in Figure 6C. TLR-7 agonists repolarize immunosuppressive M2 phenotype to immunostimulatory M1 phenotype and promote tumor cell phagocytosis.